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Table  I. In vitro effect of  hemodilution on whole blood clotting time (seconds) 
Degree of hemodilution 
Stimulus Pathway Controls 25% 50% 75% 
Celite Intrinsic 459 _+ 75 442 _+ 67 488 _+ 94 951 ± 154" 
Thromboplastin extrinsic 294 ± 29 251 + 21 277 ± 34 355 _+ 61 
Thrombin common 165 ± 51 113 + 58 91 -- 34 55 ± 19 
Values are expressed asmean -+ standard eviation. 
*In 9 of 10 samples clotting time was more than 1000 seconds 
Tab le  I I .  Clinical observation in neonates undergoing cardiac operations 
After 5 rain 30 rain 60 rain 90 rain End 
heparinization CPB CPB CPB CPB CPB 
ACTc (sec) 669 _+ 233 980 + 63* 992 + 63* 995 ± 15" 1000 -- 0 774 -- 214 
HiTT (sec) 168 _+ 58 163 ± 80 132 ± 31 132 _+ 53 118 _+ 53 95 ± 30 
Heparin (IU/ml) 2.7 _+ 0.4 1.2 ± 0.5 1.1 ± 0.5 1.3 -- 0.4 1.2 +_ 0.5 0.8 ± 0.3 
Values are expressed asmean + standard eviation. ACTc, Celite activated clotting time; HiTT, high-dose thrombin time; CPB, cardiopulmonary bypass. 
*In 9 of 10 samples ACTc was greater than 1000 seconds. 
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THE USE OF BIOLOGIC GLUE FOR BETTER ADHESIONS BETWEEN THE SKELETAL MUSCLE 
FLAP AND THE MYOCARDIUM AND FOR INCREASING CAPILLARY INGROWTH 
Valeri Chekanov, MD, PhD, Victor Nikolaychik, MD, PhD, and Guennady Tchekanov, MD, Milwaukee, Wis. 
To date, dynamic ardiomyoplasty relies on use of a properly 
conditioned, adequately contracting autogenous muscle flap for 
the correction of myocardial insutficiency. Despite its advan- 
tages, cardiomyoplasty has some unresolved problems: (1) poor 
angiogenic potential of the ischemic, traumatized skeletal mus- 
cle and damaged myocardium and (2) incomplete contact 
between the mobile myocardial wall and the transplanted flap. 
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These problems manifest hemselves after the opertion. The 
vascular supply is not reintroduced until 6 to 8 months after the 
operation. Some patients have died of recurrent myocardial 
infarction 3 to 5 months after cardiomyoplasty, before a new 
blood supply from the skeletal muscle to the myocardium had 
been established. I'2 This is the situation that needs to be 
resolved. Cardiomyoplasty done with skeletal muscle can pro- 
vide capillary ingro,m~h to the myocardium, but it may be too 
late for some patients. 
A novel approach to resolving these problems involves 
"therapeutic angiogenesis." Nine weeks after a modified 
fibrin glue (containing endothelial cell growth factor) has 
been applied between the aorta and the left ventricular 
myocardium, angiographic and histologic investigations 
have shown newly grown vascular structures between 
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Fig. 1. Macrosection 8 weeks after cardiomyoplasty. 
Strong adhesions (1) had formed between the latissimus 
dorsi muscle (2) and the myocardium (3) where the 
biologic glue was applied. No adhesions had formed in the 
area without biologic glue (4). 
these sites. 3 The results of this study confirm previous 
observations that site-directed neovessel formation can be 
induced by application an angiogenic growth factor. 4' s 
We have implemented the idea of using biologic glue 
based on a fibrinogen-thrombin composition for cardio- 
myoplasty. Fibrinogen, the main component of biologic 
glue, was prepared from donor animals by a standard 
cryoprecipitation technique. In brief, whole blood ob- 
tained from the donor was centrifuged and the plasma 
decanted. After the plasma had been frozen for 12 hours 
at -80  ° C, it was thawed at 4 ° C for 4 hours and then 
centrifuged. The yellowish white precipitate that re- 
mained after decantation was collected and stored at -18 ° 
C. The resulting cryoprecipitate contained concentrated 
fibrinogen, factor XIII, fibronectin, and vitronectin. In 
other experiments pure fibrinogen from sheep plasma 
(F-9754, Sigma Chemical Company, St. Louis, Mo.) was 
used. Thrombin was purchased from Johnson & Johnson 
Patient Care, Inc. (New Brunswick, N.J.). In both cases, 
final solutions of fibrinogen and thrombin were prepared 
in separate delivery systems. After mobilization of the 
latissimus dorsi muscle in adult sheep, the muscle was 
introduced into the thoracic cavity and wrapped around 
the heart. The muscle flap was sutured to the myocardium 
of the left ventricle and two isolated pockets were created. 
Fig. 2. Histologic examination obtained from a macro- 
section 8 weeks after cardiomyoplasty and biologic glue 
application showed vascular growth within the biologic 
glue (1). Note new blood vessels of significant diameter 
(5) and growth between the myocardium (3) and the 
latissimus dorsi muscle (2). 
In one of the pockets the biologic glue was introduced by 
simultaneously applying the two separate solutions of 
fibrinogen and thrombin between the skeletal muscle and 
myocardium. The amount of glue used per animal was in 
the range of 20 to 30 ml. As a control, no biologic glue was 
introduced in the other pocket. After the operation the 
animals had the usual postoperative management and the 
typical stimulation protocol for skeletal muscle training. 
After 8 weeks we examined the muscle flap and the 
myocardium of the left ventricle (Fig. 1). We saw ex- 
tremely strong adhesions between the latissimus dorsi 
muscle and the myocardium in the pocket where the 
biologic glue had been applied. Histologic examination 
showed new blood vessel growth of significant diameter 
(Fig. 2). No adhesions had developed in the areas inwhich 
biologic glue was not used. 
In summary, we have shown that we can induce signif- 
icant formation of new blood vessel structures and pro- 
duce strong adhesions between the myocardium and 
skeletal muscle with the use of biologic glue. This finding 
may be helpful for patients undergoing cardiomyoplasty. 
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Enhancement of angiogenesis and vasculogenesis after 
cardiomyoplasty might be achieved by local implantation 
of autologous endothelial cells cultured ex vivo or by 
application of angiogenic factors like vascular endothelial 
growth factor, platelet-derived growth factor, insulin-like 
growth factor, fibroblast growth factor, or extracellular 
matrix components like fibronectin, laminin, and proteo- 
glycans. From this point of view, the fibrin meshwork 
serves only as a local delivery depot. However, it seems to 
us that a pure fibrin meshwork can sufficiently mimic the 
extracellular matrix for endothelial cells and support heir 
growth. We believe that further study is required to assess 
the potential of various growth factors and suppressors of
ischemia- reperfusi0n lesions in shortening the recovery 
period between surgery and full assistance in pumping 
functions of the native heart. 
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